Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
NCT03290079Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2017
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in Neuroendocrine Neoplasm (NEN), sponsored by Moffitt Cancer Center. Started Dec 2017; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03290079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03290079.